An Open-Label Phase 1b Trial of Lenvatinib Plus Pembrolizumab in Subjects With Hepatocellular Carcinoma
Phase of Trial: Phase I
Latest Information Update: 16 May 2018
At a glance
- Drugs Lenvatinib (Primary) ; Pembrolizumab (Primary)
- Indications Liver cancer
- Focus Adverse reactions
- Acronyms KEYNOTE-524
- Sponsors Eisai Co Ltd
- 16 May 2018 According to a Merck & Co media release, data from this trial will be presented at the 54th Annual Meeting of the American Society of Clinical Oncology (ASCO) 2018.
- 15 Sep 2017 Planned End Date changed from 1 Jun 2019 to 28 Feb 2019.
- 15 Sep 2017 Planned primary completion date changed from 1 Dec 2018 to 31 Aug 2018.